CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Propranolol Hydrochloride Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2023-10-31. Latest FDA row update: 2026-09-18.
FDA lists 2 package records, with companies: Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc.. Package NDCs: 0143-9872-10, 63323-604-01.
FDA shortage reason: Shortage of an active ingredient
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Fresenius Kabi USA, LLC | 63323-604-01 | Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01) | Available | 2026-09-15 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9872-10 | Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10) | Unavailable | 2026-09-18 |
Source facts
Grouped generic ingredient: Propranolol Hydrochloride Injection · 2 package records
Therapeutic categories: Cardiovascular
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.